Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Director Daniel N. Swisher Jr. of Corcept Therapeutics Inc (NASDAQ:CORT), a company currently valued at $7.76 billion, sold 2,200 shares of common stock on August 11, 2025, at a price of $72.30, totaling $159,060. The sale was executed under a pre-arranged 10b5-1 trading plan adopted August 1, 2024. According to InvestingPro, CORT has delivered an impressive 115.74% return over the past year, with analysts setting price targets between $121 and $145.
On the same day, Swisher also exercised options to acquire 2,200 shares of Corcept Therapeutics at an exercise price of $14.08, for a total value of $30976. Following the option exercise, Swisher directly owns 5,500 shares. These options are fully exercisable and expire on August 20, 2028. The company maintains a GREAT financial health score on InvestingPro, which offers 12 additional valuable insights about CORT’s performance and valuation in its comprehensive Pro Research Report.
In other recent news, Corcept Therapeutics reported its second-quarter 2025 earnings, which exceeded expectations on earnings per share (EPS) but fell short on revenue. The company announced an EPS of $0.29, surpassing the forecasted $0.19 by 52.63%. However, its revenue was $194.4 million, slightly missing the anticipated $199.4 million by 2.51%. This mixed result comes amidst ongoing supply chain challenges. Despite the EPS success, the revenue shortfall seemed to weigh on investor sentiment. These developments occurred alongside a 3.92% decline in after-hours trading. The company’s performance and related market reactions highlight the complexities faced by Corcept Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.